Publication date: Feb 08, 2020
Recent evidence suggests a potential role for mixed proteinopathies in the development of clinical manifestations in patients with Huntington’s disease (HD). A possible cross-talk between mutant huntingtin and ?-synuclein aggregates has been postulated. Serum ?-synuclein has been evaluated as a potential biomarker in patients with Parkinson’s disease. We presently sought to investigate serum ?-synuclein levels in 38 HD patients (34 symptomatic and 4 premanifest) and compare them to 36 controls. We found that ?-synuclein was elevated in HD patients vs. controls (2.49 +/- 1.47 vs. 1.40 +/- 1.16, p=0.001). There was no difference in ?-synuclein levels between symptomatic vs. premanifest HD, nor between HD patients receiving medication vs. treatment-na”ive. Furthermore, ?-synuclein levels showed no correlation with CAG2, Unified HD Rating Scale motor score, age, disease duration or disease burden score. Our results provide evidence for elevated serum ?-synuclein in HD and lend support to further investigating the role of ?-synuclein in this disorder.
|Nave||Peripheral membrane proteins|
|Serum||Branches of biology|
- Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington’s disease.